Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2011-03-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Participation in a Research Registry for Immune Disorders
NCT01953016
Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders
NCT00001351
COVID-19 Immune Repertoire Sequencing
NCT04368143
Evaluation Study of RDTs Detecting Antibodies Against HCV
NCT04033887
Detection and Characterization of Host Defense Defects
NCT00001355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects provide consent for use of routine clinical and laboratory data for research. All data is collected by a combination of retrospective medical note review and extraction of data from electronic health records. At a minimum, the following data items are to be collected at enrolment and subsequent clinic visits:
1. Demography and basic information (e.g. date of birth, gender, country of origin, ethnicity, anthropometric assessments, and reasons for the attendance, date or year for disease diagnosis and transmission risk.
2. Laboratory data: Relevant routine virological (including genotyping) and immunological data for characterisation of the HIV infection, TB, hepatitis C, COVID-19 and other relevant co-infections will also be collected as well as other relevant clinical routine data on tolerability and safety (i.e., renal, liver, lipids)
3. Medical treatment: All medications, including start-and stop dates and reason for discontinuation, adherence. Concomitant medical treatment related to co-infections and co-morbidities.
4. Clinical events: hospitalisation, diseases specific relevant active and previous diagnosis (e.g., AIDS and non-AIDS events, including comorbidities).
In addition, subjects are asked to provide biological samples for up to five occasions every six months for bio-banking for host profiling and pathogen bio-repository. To provide flexibility for participants around requirements for fasting or scheduling, participants may be asked to attend to provide samples for biobanking outside of routine scheduled clinic visits. These stored samples provide the opportunity for future research studies investigating host factors associated with the response to infection.
The AIID Cohort is approved by local institutional review boards and all participants provide written, informed consent. Data and samples within the AIID Cohort are accessed through standardised Data Access Guidelines and all approved Data Access Requests are approved by the local Ethics Committee.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to provide informed consent or
* Provide deferred assent if an incapacitated or unconscious patient is unable to provide informed consent
Exclusion Criteria
* Patients with learning disabilities, mental illness, or dementia
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beaumont Hospital
OTHER
Children's Health Ireland
OTHER_GOV
Cork University Hospital
OTHER
Mater Misericordiae University Hospital
OTHER
Our Lady of Lourdes Hospital, Drogheda
OTHER_GOV
St. James's Hospital, Ireland
OTHER
St. Luke's Hospital, Ireland
OTHER
St Vincent's University Hospital, Ireland
OTHER
Wexford General Hospital
UNKNOWN
University College Dublin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patrick Mallon, PhD, FRCPI
Role: PRINCIPAL_INVESTIGATOR
UCD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cork University Hospital
Cork, , Ireland
Our Lady of Lourdes Hospital, Drogheda
Drogheda, , Ireland
St Vincent's University Hospital, Ireland
Dublin, , Ireland
Mater Misericordiae University Hospital
Dublin, , Ireland
Beaumont Hospital
Dublin, , Ireland
Children's Health Ireland at Crumlin
Dublin, , Ireland
St James's Hospital
Dublin, , Ireland
St Luke's General Hospital, Kilkenny
Kilkenny, , Ireland
Wexford General Hospital
Wexford, , Ireland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Corina Sadlier, Dr
Role: primary
Justin Low, Dr
Role: primary
Eoin Feeney, Dr
Role: primary
Aoife Cotter, Dr
Role: primary
Alan Macken
Role: backup
Eoghan De Barra, Dr
Role: primary
Paddy Galvin, Dr
Role: primary
Fiona Lyons, Dr
Role: primary
Garry Courtney, Dr
Role: primary
Obada Yousef, Dr
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AIID Cohort
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.